Table 1.
Characteristics | All samples N Percentage (%) |
Training N Percentage (%) |
Validation N Percentage (%) |
P | |||
---|---|---|---|---|---|---|---|
Age(years) | |||||||
<65 years | 855 | 44.16% | 584 | 44.44% | 271 | 43.57% | 0.7172 |
>65 years | 1081 | 55.84% | 730 | 55.56% | 351 | 56.43% | |
Sex | |||||||
female | 538 | 27.79% | 379 | 28.84% | 159 | 25.56% | 0.1324 |
male | 1398 | 72.21% | 935 | 71.16% | 463 | 74.44% | |
Race | |||||||
American Indian/Alaska Native | 16 | 0.83% | 10 | 0.76% | 6 | 0.96% | 0.6237 |
Asian/Pacific Islander | 209 | 10.80% | 143 | 10.88% | 66 | 10.61% | |
Black | 323 | 16.68% | 216 | 16.44% | 107 | 17.20% | |
White | 1388 | 71.69% | 945 | 71.92% | 443 | 71.22% | |
Primary Site | |||||||
Cardia | 802 | 41.43% | 551 | 41.93% | 251 | 40.35% | 0.4580 |
Pylorus | 95 | 4.91% | 62 | 4.72% | 33 | 5.31% | |
Body | 169 | 8.73% | 118 | 8.98% | 51 | 8.20% | |
Antrum | 308 | 15.91% | 208 | 15.83% | 100 | 16.08% | |
Fundus | 28 | 1.44% | 19 | 1.45% | 9 | 1.45% | |
Lesser curve | 119 | 6.14% | 80 | 6.09% | 39 | 6.27% | |
Greater curve | 67 | 3.46% | 46 | 3.50% | 21 | 3.38% | |
Other | 348 | 17.98% | 230 | 17.50% | 118 | 18.97% | |
Histologic type | |||||||
Adenocarcinoma | 1609 | 83.11% | 1089 | 82.88% | 520 | 83.60% | 0.6867 |
Signet ring cell | 137 | 7.08% | 95 | 7.23% | 42 | 6.75% | |
Special type | 190 | 9.81% | 130 | 9.89% | 60 | 9.65% | |
Grade | |||||||
I | 57 | 2.94% | 41 | 3.12% | 16 | 2.57% | 0.4192 |
II | 621 | 32.08% | 416 | 31.66% | 205 | 32.96% | |
III | 1214 | 62.71% | 834 | 63.47% | 380 | 61.09% | |
IV | 44 | 2.27% | 23 | 1.75% | 21 | 3.38% | |
T Stage | |||||||
T0 | 3 | 0.15% | 2 | 0.15% | 1 | 0.16% | 0.7041 |
T1 | 759 | 39.20% | 520 | 39.57% | 239 | 38.49% | |
T2 | 110 | 5.68% | 71 | 5.40% | 39 | 6.28% | |
T3 | 461 | 23.81% | 311 | 23.67% | 150 | 24.15% | |
T4 | 603 | 31.15% | 410 | 31.20% | 193 | 31.08% | |
N Stage | |||||||
N0 | 756 | 39.05% | 516 | 39.27% | 240 | 38.59% | 0.7374 |
N1 | 864 | 44.63% | 583 | 44.37% | 281 | 45.18% | |
N2 | 158 | 8.16% | 108 | 8.22% | 50 | 8.04% | |
N3 | 158 | 8.16% | 107 | 8.14% | 51 | 8.20% | |
Radiotherapy | |||||||
Yes | 359 | 18.54% | 235 | 17.88% | 124 | 19.94% | 0.2781 |
No | 1577 | 81.46% | 1079 | 82.12% | 498 | 80.06% | |
Chemotherapy | |||||||
Yes | 1171 | 60.73% | 803 | 59.61% | 368 | 63.35% | 0.4131 |
No | 765 | 39.27% | 511 | 40.39% | 254 | 36.65% | |
Surgery | |||||||
Yes | 298 | 15.39% | 199 | 15.14% | 99 | 15.92% | 0.6604 |
No | 1638 | 84.61% | 1115 | 84.86% | 523 | 84.08% | |
Bone Metastasis | |||||||
Yes | 157 | 8.85% | 110 | 8.37% | 62 | 9.97% | 0.2490 |
No | 1618 | 91.15% | 1204 | 91.63% | 560 | 90.03% | |
Brain Metastasis | |||||||
Yes | 26 | 1.34% | 14 | 1.07% | 12 | 1.93% | 0.1231 |
No | 1910 | 98.66% | 1300 | 98.93% | 610 | 98.07% | |
Lung Metastasis | |||||||
Yes | 315 | 16.27% | 209 | 15.91% | 106 | 17.04% | 0.5271 |
No | 1621 | 83.73% | 1105 | 84.09% | 516 | 82.96% | |
Marital Status | |||||||
Yes | 1191 | 61.52% | 820 | 62.40% | 371 | 59.65% | 0.2441 |
No | 745 | 38.48% | 494 | 37.60% | 251 | 40.35% |